A Low Level of Darunavir Resistance-Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort.
HIV-1
darunavir
genotype
mutation rate
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
07
09
2020
accepted:
18
11
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
8
1
2021
Statut:
epublish
Résumé
Ritonavir-boosted darunavir (DRV/r) is a protease inhibitor (PI) indicated for the treatment of naïve and pretreated HIV-infected patients since 2007. Our study aims to describe DRV/r-treated patients experiencing virological failure (VF) documented with HIV resistance testing. Data from patients belonging to the ANRS CO3 Aquitaine Cohort treated with a regimen including DRV/r between February 2007 and December 2015 were analyzed. Baseline characteristics of patients experiencing VF (defined by 2 consecutive plasma viral loads >50 copies/mL) were compared with those without VF. We then described factors associated with VF as emergence of IAS DRV resistance-associated mutations (RAMs). Among the 1458 patients treated at least once with a DRV/r-based regimen, 270 (18.5%) patients experienced VF during follow-up, including 240 with at least 1 genotype resistance test (GRT). DRV RAMs were detected in 29 patients (12%). Among them, 25/29 patients had ≥2 DRV RAMs before DRV/r initiation, all of whom had experienced VF during previous PI treatments. For 18/29, DRV/r was maintained after VF, and controlled viremia was restored after modification of DRV-associated antiretroviral molecules or increased DRV dose. Finally, only 6/29 patients selected new DRV RAMs after DRV/r initiation. All of these experienced previous VFs while on other PIs. These results highlight the efficacy and robustness of DRV/r, as the emergence of DRV RAMs appeared in <0.4% of patients receiving a DRV/r-based regimen in our large cohort.
Sections du résumé
BACKGROUND
BACKGROUND
Ritonavir-boosted darunavir (DRV/r) is a protease inhibitor (PI) indicated for the treatment of naïve and pretreated HIV-infected patients since 2007. Our study aims to describe DRV/r-treated patients experiencing virological failure (VF) documented with HIV resistance testing.
METHODS
METHODS
Data from patients belonging to the ANRS CO3 Aquitaine Cohort treated with a regimen including DRV/r between February 2007 and December 2015 were analyzed. Baseline characteristics of patients experiencing VF (defined by 2 consecutive plasma viral loads >50 copies/mL) were compared with those without VF. We then described factors associated with VF as emergence of IAS DRV resistance-associated mutations (RAMs).
RESULTS
RESULTS
Among the 1458 patients treated at least once with a DRV/r-based regimen, 270 (18.5%) patients experienced VF during follow-up, including 240 with at least 1 genotype resistance test (GRT). DRV RAMs were detected in 29 patients (12%). Among them, 25/29 patients had ≥2 DRV RAMs before DRV/r initiation, all of whom had experienced VF during previous PI treatments. For 18/29, DRV/r was maintained after VF, and controlled viremia was restored after modification of DRV-associated antiretroviral molecules or increased DRV dose. Finally, only 6/29 patients selected new DRV RAMs after DRV/r initiation. All of these experienced previous VFs while on other PIs.
CONCLUSIONS
CONCLUSIONS
These results highlight the efficacy and robustness of DRV/r, as the emergence of DRV RAMs appeared in <0.4% of patients receiving a DRV/r-based regimen in our large cohort.
Identifiants
pubmed: 33409332
doi: 10.1093/ofid/ofaa567
pii: ofaa567
pmc: PMC7772944
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa567Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
HIV Med. 2020 Nov;21(10):617-624
pubmed: 32885559
AIDS. 2010 Mar 27;24(6):921-4
pubmed: 20160633
Antivir Ther. 2009;14(6):859-64
pubmed: 19812449
J Clin Virol. 2010 Mar;47(3):248-52
pubmed: 20097121
HIV Med. 2012 Aug;13(7):398-405
pubmed: 22413874
Sci Rep. 2018 Mar 27;8(1):5288
pubmed: 29588457
N Engl J Med. 1998 Mar 26;338(13):853-60
pubmed: 9516219
J Med Virol. 2016 Dec;88(12):2125-2131
pubmed: 27218208
AIDS. 2007 May 31;21(9):1210-3
pubmed: 17502734
Clin Infect Dis. 2009 Nov 1;49(9):1441-9
pubmed: 19814627
mBio. 2018 Mar 6;9(2):
pubmed: 29511083
Lancet. 2007 Apr 7;369(9568):1169-78
pubmed: 17416261
J Antimicrob Chemother. 2017 Jun 1;72(6):1769-1773
pubmed: 28333232
J Antimicrob Chemother. 2019 Nov 1;74(11):3305-3314
pubmed: 31384941
J Antimicrob Chemother. 2016 Dec;71(12):3487-3494
pubmed: 27856703
HIV Med. 2013 Jan;14(1):49-59
pubmed: 23088336
J Antimicrob Chemother. 2007 Oct;60(4):885-8
pubmed: 17646201
Clin Infect Dis. 2020 Oct 23;71(7):e170-e177
pubmed: 31724034
AIDS. 2011 Apr 24;25(7):929-39
pubmed: 21346512
Clin Infect Dis. 2017 Nov 29;65(12):2112-2118
pubmed: 29020293
Antivir Ther. 2013;18(3):289-300
pubmed: 23558157
HIV Clin Trials. 2018 Dec;19(6):242-248
pubmed: 30890064
AIDS Res Hum Retroviruses. 2018 May;34(5):471-473
pubmed: 29439582
J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):179-82
pubmed: 18769351